Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGTR1 | P30556 | 8/20 | 0.47 |
| ▸ | AGTR2 | P50052 | 5/20 | 0.47 |
| ▸ | PPARG | P37231 | 3/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.44 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.44 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ACE | P12821 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.44 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.44 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.44 |
| ▸ | PDE4A | P27815 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9091939 | 0.92 | AGTR1 (0.45) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL13937415 | 0.90 | AGTR1 (0.52) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| Pomisartan SCHEMBL564508 | 0.90 | AGTR1 (0.60) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL7311530 | 0.90 | PPARG (0.46) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL9092788 | 0.89 | AGTR1 (0.46) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL9236071 | 0.89 | AGTR1 (0.44) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL7304823 | 0.88 | AGTR1 (0.49) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL7311125 | 0.87 | AGTR1 (0.43) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL9091885 | 0.85 | AGTR1 (0.45) | AGTR1AGTR2PPARGALDH1A1KDM4E | |
| SCHEMBL7303109 | 0.84 | PPARG (0.55) | AGTR1AGTR2PPARGALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NITROMED, INC. (US) | 2009-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090215838-A1 | ORGANIC NITRIC OXIDE ENHANCING SALTS OF ANGIOTENSIN II ANTAGONISTS, COMPOSITIONS AND METHODS OF USE | NOS2, NOS3, NOS1 | AGTR1 5/4885AGTR2 4/4885PPARG 727/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.